Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

A Novel Polymer Based Antidote for Reversing the Anticoagulation Effect of Clinically Used Heparins,

Rajesh A Shenoi, PhD, Benjamin F L Lai, MSc, Dirk Lange, PhD, Donald E Brooks, PhD, Ben Chew, MD, Cedric John Carter, MD, Jayachandran N Kizhakkedathu, PhD

Blood (2011) 118 (21): 3359.

https://doi.org/10.1182/blood.V118.21.3359.3359

Published: 2011

Journal Articles

Idrabiotaparinux, a Biotinylated Long-Acting Anticoagulant, in the Treatment of Deep Venous Thrombosis (EQUINOX Study): Safety, Efficacy, and Reversibility by Avidin

Harry Roger Buller, MD, PhD, Jean-Michel Destors, Alexander S. Gallus, MD, Martin H Prins, MD, PhD, Gary Edward Raskob, PhD

Blood (2008) 112 (11): 32.

https://doi.org/10.1182/blood.V112.11.32.32

Published: 2008

Journal Articles

Bleeding and Thromboembolic Events after Termination of Therapy with Idraparinux for Prevention of Recurrent Venous Thromboembolism-Observation after the van Gogh Trials.

Job Harenberg, MD, Ingrid Joerg, MD, Antje Hagedorn, Christina Giese

Blood (2007) 110 (11): 1877.

https://doi.org/10.1182/blood.V110.11.1877.1877

Published: 2007

Journal Articles

Pharmacodynamic Analysis of the Anticoagulant Effects of Idraparinuxparinux after Termination of 6 and 12 Months Therapy for Prevention of Recurrent Venous Thromboembolism: Observations after the vanGogh Trials.

Job Harenberg, MD, Ingrid Joerg, Antje Hagedorn, Christina Giese, Christel Weiss, Gerd Mikus

Blood (2007) 110 (11): 1883.

https://doi.org/10.1182/blood.V110.11.1883.1883

Published: 2007

Journal Articles

Once Weekly Subcutaneous Idraparinux Versus Placebo in the Extended Treatment of Deep-Vein Thrombosis or Pulmonary Embolism. The van Gogh Investigators.

Harry R. Buller, MD, on Behalf of the Van Gogh Investigators

Blood (2006) 108 (11): 571.

https://doi.org/10.1182/blood.V108.11.571.571

Published: 2006

Journal Articles

Evaluation of Once Weekly Subcutaneous Idraparinux Versus Standard Therapy with Heparin and Vitamin K Antagonists in the Treatment of Deep-Vein Thrombosis or Pulmonary Embolism - The Van Gogh Investigators.

Harry R. Buller, MD, on Behalf of the Van Gogh Investigators

Blood (2006) 108 (11): 6.

https://doi.org/10.1182/blood.V108.11.6.6

Published: 2006

Journal Articles

Long Acting Anticoagulant Effects of Idraparinux in Patients Treated for Prophylaxis of Recurrent Venous Thromboembolism.

Job Harenberg, Ingrid Joerg, M.D., Christel Weiss, M.D., Tivadar Fenyvesi, M.D.

Blood (2006) 108 (11): 899.

https://doi.org/10.1182/blood.V108.11.899.899

Published: 2006

NARROW

A Novel Polymer Based Antidote for Reversing the Anticoagulation Effect of Clinically Used Heparins,

Idrabiotaparinux, a Biotinylated Long-Acting Anticoagulant, in the Treatment of Deep Venous Thrombosis (EQUINOX Study): Safety, Efficacy, and Reversibility by Avidin

Bleeding and Thromboembolic Events after Termination of Therapy with Idraparinux for Prevention of Recurrent Venous Thromboembolism-Observation after the van Gogh Trials.

Pharmacodynamic Analysis of the Anticoagulant Effects of Idraparinuxparinux after Termination of 6 and 12 Months Therapy for Prevention of Recurrent Venous Thromboembolism: Observations after the vanGogh Trials.

Once Weekly Subcutaneous Idraparinux Versus Placebo in the Extended Treatment of Deep-Vein Thrombosis or Pulmonary Embolism. The van Gogh Investigators.

Evaluation of Once Weekly Subcutaneous Idraparinux Versus Standard Therapy with Heparin and Vitamin K Antagonists in the Treatment of Deep-Vein Thrombosis or Pulmonary Embolism - The Van Gogh Investigators.

Long Acting Anticoagulant Effects of Idraparinux in Patients Treated for Prophylaxis of Recurrent Venous Thromboembolism.

Email alerts

ASH Publications

American Society of Hematology

A Novel Polymer Based Antidote for Reversing the Anticoagulation Effect of Clinically Used Heparins,

Idrabiotaparinux, a Biotinylated Long-Acting Anticoagulant, in the Treatment of Deep Venous Thrombosis (EQUINOX Study): Safety, Efficacy, and Reversibility by Avidin

Bleeding and Thromboembolic Events after Termination of Therapy with Idraparinux for Prevention of Recurrent Venous Thromboembolism-Observation after the van Gogh Trials.

Pharmacodynamic Analysis of the Anticoagulant Effects of Idraparinuxparinux after Termination of 6 and 12 Months Therapy for Prevention of Recurrent Venous Thromboembolism: Observations after the vanGogh Trials.

Once Weekly Subcutaneous Idraparinux Versus Placebo in the Extended Treatment of Deep-Vein Thrombosis or Pulmonary Embolism. The van Gogh Investigators.

Evaluation of Once Weekly Subcutaneous Idraparinux Versus Standard Therapy with Heparin and Vitamin K Antagonists in the Treatment of Deep-Vein Thrombosis or Pulmonary Embolism - The Van Gogh Investigators.

Long Acting Anticoagulant Effects of Idraparinux in Patients Treated for Prophylaxis of Recurrent Venous Thromboembolism.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only